Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24540649 | 0.82 | SMN1; SMN2 (0.37) | MAPTATRPRKACAPRKACGPRKACB | |
| SCHEMBL24540737 | 0.80 | PRKACA (0.34) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL18291309 | 0.78 | ACVR1 (0.41) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL20038413 | 0.78 | ACVR1 (0.41) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL24547883 | 0.78 | MAPT (0.37) | GPR174MAPTCSF1R | |
| SCHEMBL30920981 | 0.75 | PRKACA (0.38) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL20037455 | 0.75 | DRD2 (0.48) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL20038364 | 0.75 | PRKACA (0.38) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL20037654 | 0.75 | DRD2 (0.48) | ATRPRKACAPRKACGPRKACBACVR1 | |
| SCHEMBL27392495 | 0.75 | PRKACA (0.38) | ATRPRKACAPRKACGPRKACBACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732837-A2 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11845760-B2 | PRMT5 inhibitors | AMGEN INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | GPR174 4267/4885MAPT 3592/4885ATR 672/4885 |
| US-11845760-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | GPR174 4384/4885MAPT 3444/4885ATR 769/4885 |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | GPR174 4267/4885MAPT 3592/4885ATR 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.